Stony Brook University

About: Stony Brook University is a education organization based out in Stony Brook, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 32534 authors who have published 68218 publications receiving 3035131 citations. The organization is also known as: State University of New York at Stony Brook & SUNY Stony Brook.

Quantum oscillations in two coupled charge qubits.

Abstract: A practical quantum computer, if built, would consist of a set of coupled two-level quantum systems (qubits). Among the variety of qubits implemented, solid-state qubits are of particular interest because of their potential suitability for integrated devices. A variety of qubits based on Josephson junctions have been implemented; these exploit the coherence of Cooper-pair tunnelling in the superconducting state. Despite apparent progress in the implementation of individual solid-state qubits, there have been no experimental reports of multiple qubit gates--a basic requirement for building a real quantum computer. Here we demonstrate a Josephson circuit consisting of two coupled charge qubits. Using a pulse technique, we coherently mix quantum states and observe quantum oscillations, the spectrum of which reflects interaction between the qubits. Our results demonstrate the feasibility of coupling multiple solid-state qubits, and indicate the existence of entangled two-qubit states.

Outcomes of an Emergent Literacy Intervention in Head Start.

Abstract: Classrooms of 4-year-olds attending Head Start were randomly assigned to an intervention condition, involving an add-on emergent literacy curriculum, or a control condition, involving the regular Head Start curriculum. Children in the intervention condition experienced interactive book reading at home and in the classroom as well as a classroom-based sound and letter awareness program. Children were pretested and posttested on standardized tests of language, writing, linguistic awareness, and print concepts

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

Abstract: Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we find that PDO therapeutic profiles paralleled patient outcomes and that PDOs enable longitudinal assessment of chemo-sensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemo-sensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemo-refractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.

Abstract: Background: Interferon β (IFNβ) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial. Methods: This randomized, controlled, multicenter trial compared the efficacy and safety of IFNβ-1a (Rebif®) 44 μg subcutaneously three times weekly (tiw), and IFNβ-1a (Avonex®) 30 μg IM once weekly (qw) in 677 patients with RRMS. Assessors blinded to treatment performed neurologic and MRI evaluations. The primary endpoint was the proportion of patients who were relapse free at 24 weeks; the principal MRI endpoint was the number of active lesions per patient per scan at 24 weeks. Results: After 24 weeks, 74.9% (254/339) of patients receiving IFNβ-1a 44 μg tiw remained relapse free compared with 63.3% (214/338) of those given 30 μg qw. The odds ratio for remaining relapse free was 1.9 (95% CI, 1.3 to 2.6; p = 0.0005) at 24 weeks and 1.5 (95% CI, 1.1 to 2.1; p = 0.009) at 48 weeks, favoring 44 μg tiw. Patients receiving 44 μg tiw had fewer active MRI lesions ( p p p = 0.002) and altered leukocyte counts (11% vs 5%, p = 0.003) compared with the 30 μg qw dosage. Neutralizing antibodies developed in 25% of 44 μg tiw patients and in 2% of patients receiving 30 μg qw. Conclusions: IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ-1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.